Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Foghorn Therapeutics Inc (FHTX)

Foghorn Therapeutics Inc (FHTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 286,456
  • Shares Outstanding, K 58,700
  • Annual Sales, $ 30,910 K
  • Annual Income, $ -74,280 K
  • EBIT $ -82 M
  • EBITDA $ -81 M
  • 60-Month Beta 3.02
  • Price/Sales 9.61
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 166.03% (-35.50%)
  • Historical Volatility 63.19%
  • IV Percentile 16%
  • IV Rank 7.33%
  • IV High 1,235.31% on 01/05/26
  • IV Low 81.47% on 08/18/25
  • Expected Move (DTE 28) 0.00 (0.00%)
  • Put/Call Vol Ratio 4.00
  • Today's Volume 5
  • Volume Avg (30-Day) 20
  • Put/Call OI Ratio 1.47
  • Today's Open Interest 437
  • Open Int (30-Day) 403
  • Expected Range 4.89 to 4.89

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.28
  • Number of Estimates 4
  • High Estimate -0.22
  • Low Estimate -0.32
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +6.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.59 +6.42%
on 03/12/26
5.96 -17.95%
on 02/25/26
-0.94 (-16.12%)
since 02/19/26
3-Month
4.59 +6.42%
on 03/12/26
6.95 -29.64%
on 01/13/26
-0.35 (-6.68%)
since 12/19/25
52-Week
2.94 +66.06%
on 04/03/25
6.95 -29.64%
on 01/13/26
+0.45 (+10.14%)
since 03/19/25

Most Recent Stories

More News
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook

FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC) Selective CBP degrader program with potential...

FHTX : 4.89 (+0.20%)
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences

WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...

FHTX : 4.89 (+0.20%)
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer

WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...

FHTX : 4.89 (+0.20%)
Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit

WATERTOWN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...

FHTX : 4.89 (+0.20%)
Hard-to-Treat Cancers: How 2026’s Top Clinical Platforms Are Beating Industry Benchmarks

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The global oncology market is charging toward a massive $668 billion valuation by 2034[1], fueled by a...

ONCY : 0.9789 (+1.92%)
FHTX : 4.89 (+0.20%)
ORIC : 11.10 (+2.21%)
LLY : 917.50 (-0.06%)
GOVX : 1.4300 (+0.70%)
SLS : 5.20 (+5.05%)
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium

WATERTOWN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...

FHTX : 4.89 (+0.20%)
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026

Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13 th , 2026 ...

FHTX : 4.89 (+0.20%)
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...

FHTX : 4.89 (+0.20%)
Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update

Ongoing FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1)-mutated cancer remains on track with non-small cell lung cancer (NSCLC) as the primary target population  Selective CBP...

FHTX : 4.89 (+0.20%)
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...

FHTX : 4.89 (+0.20%)

Business Summary

Foghorn Therapeutics Inc. engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system. Foghorn Therapeutics Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 5.21
2nd Resistance Point 5.08
1st Resistance Point 4.99
Last Price 4.89
1st Support Level 4.77
2nd Support Level 4.64
3rd Support Level 4.55

See More

52-Week High 6.95
Fibonacci 61.8% 5.42
Fibonacci 50% 4.95
Last Price 4.89
Fibonacci 38.2% 4.47
52-Week Low 2.94

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar